We scanned throughout chromosome 21 to assess genetic associations with late-onset Alzheimer disease (AD) using 374 Japanese patients and 375 population-based controls, because trisomy 21 is known to be associated with early deposition of b-amyloid (Ab) in the brain. Among 417 markers spanning 33 Mb, 22 markers showed associations with either the allele or the genotype frequency (P < 0.05). Logistic regression analysis with age, sex and apolipoprotein E (APOE)-14 dose supported genetic risk of 17 markers, of which eight markers were linked to the SAMSN1, PRSS7, NCAM2, RUNX1, DYRK1A and KCNJ6 genes. In logistic regression, the DYRK1A (dual-specificity tyrosine-regulated kinase 1A) gene, located in the Down syndrome critical region, showed the highest significance [OR 5 2.99 (95% CI: 1.72 -5.19), P 5 0.001], whereas the RUNX1 gene showed a high odds ratio [OR 5 23.3 (95% CI: 2.76 -196.5), P 5 0.038]. DYRK1A mRNA level in the hippocampus was significantly elevated in patients with AD when compared with pathological controls (P < 0.01). DYRK1A mRNA level was upregulated along with an increase in the Ab-level in the brain of transgenic mice, overproducing Ab at 9 months of age. In neuroblastoma cells, Ab induced an increase in the DYRK1A transcript, which also led to tau phosphorylation at Thr 212 under the overexpression of tau. Therefore, the upregulation of DYRK1A transcription results from Ab loading, further leading to tau phosphorylation. Our result indicates that DYRK1A could be a key molecule bridging between b-amyloid production and tau phosphorylation in AD.
INTRODUCTION
Alzheimer disease (AD) is the major cause of dementia in the elderly and is pathologically characterized by senile plaques with b-amyloid deposition (Ab) and neurofibrillary tangles harboring hyperphosphorylated tau in the brain. It is well established that familial autosomal-dominant early onset AD is mostly caused by mutations of the amyloid protein precursor (APP) and presenilin 1 and 2 (PS1 and PS2) genes (1) . In contrast, Down syndrome (DS) is also highlighted as a model condition predisposing to AD, because patients with DS develop early deposition of Ab in the brain (2) . Therefore, it has been speculated that genetic factors related to AD could exist on chromosome 21, independent of the 14 allele of the apolipoprotein E gene (APOE-14), a known strong risk for late-onset AD (3, 4) . Using the candidate approach, it was reported that duplication of the APP gene was transmitted in patients with familial autosomal-dominant early onset AD with cerebral angiopathy (5) , whereas an association with the APP gene, to the best of our knowledge, was not supported in case -control studies (6 -8) . The BACE2 gene, encoding b-secretase of APP, was not associated with AD; however, recent studies showed weak associations (9 -11) . In contrast, with the positional approach, genome scans of late-onset AD showed positive linkage on chromosome 21 (12, 13) . Although this linkage remains controversial (14 -16), a locus strongly influencing age at onset was also found on chromosome 21 (17) . To search for genetic factors for late-onset AD on chromosome 21, we scanned throughout this chromosome using patients with Japanese late-onset AD and population-based controls, by a stepwise single nucleotide polymorphism (SNP) scan. We report that the DYRK1A gene is a genetic factor related to the progression of AD.
RESULTS

Chromosome 21 scan
An exploratory scan of chromosome 21 was performed in 188 AD and 375 controls, using 417 SNPs at an average interval of ,100 kb, including at least one SNP in each coding region. Selected SNP markers were distributed between base positions 14 440 543 and 46 915 057 based on NCBI Build 35, whereas no SNP closer to the centromere was included because of the duplicated region in the chromosome 21 sequence (18) . Using a threshold of P , 0.05 for allele frequency, we detected 14 SNPs, which is less than the predicted 21 markers. Therefore, to reduce type II error, we also tested genotype frequency in both dominant and recessive models (Fig. 1) . Finally, the exploratory scan detected 42 SNPs in total (10.0%), among which 14 SNPs were significant in both allele and genotype frequencies, of which one positive region was identified in the Down syndrome critical region (DSCR) (19 -21) . The confirmatory scan targeting the selected 42 SNPs indicated that 22 SNPs were still significant for either allele or genotype frequency (Table 1) 
Haplotype analysis of DYRK1A
SNPs located in the DYRK1A gene region were genotyped to determine the haplotype associated with AD. Linkage disequilibrium was identified in the control group from 30 kb upstream of exon 1 to intron 9, but not in exon 13 genotyped by rs1803439 which was not in Hardy-Weinberg equilibrium, and the AD group showed similar results (Fig. 2) . Haplotype analysis indicated that three haplotypes had significantly different frequencies between AD and controls, whereas the permutation test supported significant differences in two haplotypes. Considering the haplotype frequencies, rs8126696 alleles could represent the risk haplotype (Table 2) . We also sequenced all coding regions of the DYRK1A gene in six patients and three controls homozygous for the risk allele, but no sequence alteration was found.
DYRK1A mRNA in hippocampus of AD DYRK1A mRNA in the hippocampus was measured by quantitative polymerase chain reaction (PCR) to examine the relation with the occurrence of AD and with the genotype of rs8126696. DYRK1A mRNA level in the patients was significantly different (P , 0.01), being 7-fold greater than that in pathological controls (Fig. 3A) . In contrast, patients homozygous for the risk rs8126696-c allele showed a tendency for a decrease in DYRK1A mRNA level compared with the others, 
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DYRK1A mRNA and Ab in transgenic mouse brain
We examined whether Ab loading is related to DYRK1A mRNA level in the brain in PS1 I213T KI and Tg-PS1/APP mice. Ab1-40 level in PS1 I213T KI mice was low, but Ab1-40 was almost undetectable, whereas both Ab1-40 and Ab1-42 were elevated in Tg-PS1/APP mice ( Fig. 4A and B) , suggesting that Tg-PS1/APP mice have an Ab burden in their brain. Quantitative PCR showed that the DYRK1A mRNA level was significantly increased in Tg-PS1/APP mice when compared with that in PS1 I213T KI mice (P , 0.05) by 1.2-fold (Fig. 4C) . Thus, the expression of DYRK1A mRNA increased along with Ab loading in the mouse brain.
DYRK1A mRNA, Ab and tau phosphorylation in cell models
We examined whether Ab, a major component of senile plaques in the AD brain, induces expression of DYRK1A mRNA in cultured neuroblastoma cells. SH-SY5Y cells were incubated with Ab, and then total RNA was extracted and quantified (Fig. 5 ). DYRK1A mRNA level was significantly increased by 1.6-fold (P , 0.05) with 0.5 mM Ab1-42 and by 1.3-fold (P , 0.01) with 25 mM Ab25 -35, compared with the level in non-treated cells, but was not changed with control 25 mM Ab35-25. Thus, Ab loading resulted in an increase in the DYRK1A transcription. In an in vitro experiment, DYRK1A protein not only phosphorylates itself, but also has a large repertoire of phosphorylation (22) . Therefore, we examined whether DYRK1A overexpression induces phosphorylation of tau at the cellular level. An immunoblot of HEK293T cells transiently transfected with the MAPT expression vector showed a detectable amount of tau along with those phosphorylated at Thr 212 (Fig. 6A) . Tau phosphorylated at Thr 212 was increased by co-transfection of the DYRK1A expression vector, compared with that of mock vector, whereas tau level was similar (Fig. 6A) . Densitometric quantification supported the induction of phosphorylation by 1.5-fold (P , 0.01) (Fig. 6B) . Thus, the increase in the DYRK1A transcription under overexpression of tau induced tau phosphorylation at Thr 212 . 
(a/t). Chi-squared for the overall haplotypes (df ¼ 6) was significant by the EM algorithm (P ¼ 0.040) as well as by the permutation method (P ¼ 0.038). 
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Discussion
Genome scanning using case -control studies, based on linkage disequilibrium, is a strategy to identify genetic factors of polygenetic diseases. In general, many susceptibility genes have been reported, but it remains difficult to replicate the results in different studies. This could possibly be caused by selection bias in patients as well as in controls, because hospital-based control subjects often suffer from another disease, leading to an additional background of that disease. Therefore, we used population-based controls to match the phenotypic background. From the exploratory and confirmatory scans, we identified 22 candidate SNPs associated with late-onset AD on chromosome 21. Although we showed their risk effects in logistic regression with age, sex and APOE-14 dose, a known major risk for AD (3), these candidates need to be confirmed, because P-values were inconclusive when considering the comparison of multiple loci. We found associations of AD with markers linked to six known genes, but not with reported candidates, the APP and BACE2 genes. The SAMSN1 gene encodes a member of putative adaptors and scaffold proteins containing SH3 and sterile alpha motif domains, expressed mainly in immune tissues and hematopoietic cells and also at lower levels in the heart, brain, placenta and lung (23) . The DYRK1A gene, located in the DSCR, is a candidate gene responsible for learning and memory impairment in patients with DS (24, 25) . The PRSS7 gene encodes enteropeptidase (EC 3.4.21.9), an intestinal enzyme initiating activation of pancreatic proteolytic proenzymes such as trypsin, chymotrypsin and carboxypeptidase A, which are highly expressed in the intestines and at a low level in the brain of rat (26) , but is downregulated in amniotic fluid cells in patients with DS (27) . The neural cell adhesion molecule 2 (NCAM2) gene is expressed in fetal and adult brains (28) , sharing many features with immunoglobulins and mediating adhesion among neurons and between neurons and muscle (29) and having a potential regulatory role in the formation of selective axonal projections of olfactory sensory neurons in mice (30) . The RUNX1 gene, also called AML1, encodes runt-related transcription factor 1, which is required for active repression in CD4-negative/ CD8-negative thymocytes, and a defective RUNX1 gene causes a familial platelet disorder with predisposition to acute myelogenous leukemia (31) . The mouse RUNX1 homolog is expressed in selected populations of post-mitotic neurons of the embryonic central and peripheral nervous systems (32) . The KCNJ6 gene, located in the DSCR, encodes a G protein-coupled inwardly rectifying potassium channel and is expressed in the brain and pancreatic beta cells (33, 34) . A kcnj6 mutation was found in the weaver mouse characterized by ataxia with reduced size of the cerebellum because of depletion of granule cell neurons (35) .
DYRK1A is a mammalian ortholog of the Drosophila minibrain gene, which is essential for normal post-embryonic neurogenesis (36) . In rodents, DYRK1A mRNA is expressed ubiquitously in various tissues during development and is also strongly expressed in the adult brain and heart (20, 37 -39) . In humans, DYRK1A mRNA is expressed especially in the brain, and immunoreactive DYRK1A is found in the cerebral cortex, hippocampus and cerebellum and is overexpressed in the DS brain in a dose-dependent manner (40, 41) . Transgenic mice overexpressing full-length DYRK1A mRNA exhibit neurodevelopmental delay, motor abnormalities and cognitive deficit, suggesting a causative role of the DYRK1A gene in mental retardation and motor anomalies of DS (24, 25) . It was noted that all adults with DS over the age of 40 years develop sufficient neuropathology for a diagnosis of AD (42) . The identification of the DYRK1A gene as a genetic factor strongly supports that the DYRK1A gene is involved in the development of AD.
We demonstrated an increase in the DYRK1A mRNA level in post-mortem brains, coinciding with the recent report of DYRK1A immunoreactivity in the neocortex and hippocampus in AD (41) . The risk genotype of the DYRK1A gene showed a tendency for a decrease in the DYRK1A mRNA level, but our observation needs to be carefully considered because the result might be caused by the reduction of neuronal cells in the AD brain. However, no studies have yet examined the relationship between the DYRK1A gene and Ab. Genetic and pathological evidence strongly supports the amyloid cascade hypothesis that Ab42, a proteolytic derivative of the APP protein, has an early and pivotal role in all cases of AD. It is thought that Ab42 forms aggregates that initiate the pathogenic cascade, leading ultimately to neural loss and dementia (43) . We demonstrated that Ab, especially Ab42, results in an increase of DYRK1A transcription in human neuroblastoma cells and is also observed in transgenic mouse models. Therefore, the increase in DYRK1A transcription is a common feature of AD and DS and could relate to the cognitive impairment in patients with AD.
The DYRK1A enzyme has dual substrate specificity: autophosphorylation for self-activation takes place on the Tyr 321 residue in the active loop of the catalytic domain (44) and target protein phosphorylation occurs on serine/threonine residues in several proteins, including STAT3, FHKR, Gli-1, eIF2B1, tau, dynamin, glycogen synthase, 14-3-3, CREB, cyclin L2, Arip4, Hip-1 and PAHX-AP1, indicating that DYRK1A may participate in many biological pathways (22) . We showed that overexpression of the DYRK1A gene phosphorylates tau at Thr 212 in HEK293T cells overproducing tau, suggesting that tau phosphorylation at Thr 212 by DYRK1A could be a downstream consequence of Ab overproduction. It was shown in an in vitro experiment that DYRK1A phosphorylates tau at Thr 212 , which primes tau for phosphorylation by GSK3-b at Ser 208 , leading to the formation of paired helical filaments composed of highly phosphorylated tau, a component of neurofibrillary tangles (41) . However, transgenic mice overexpressing DYRK1A did not show this phosphorylation, and this phosphorylation is highly susceptible to dephosphorylation by protein phosphatase-1, which is expressed in the frontal lobes of the brain, indicating that tau phosphorylation at Thr 212 could be prohibited in vivo (45, 46) . On the contrary, it was noted that peptides of tau phosphorylated at Thr 212 completely block Ab binding, and DYRK1A mediated phosphorylation of Huntingtin-interacting protein 1 (Hip-1) in response to bFGF, resulting in the blockade of Hip-1-mediated neuronal cell death as well as the enhancement of neurite outgrowth (47, 48) . Therefore, tau phosphorylation at Thr 212 could be a protective response against neuronal cell death. Although overexpression of DYRK1A could be a common phenomenon Human Molecular Genetics, 2007, Vol. 16 , No. 1between AD and DS, neuropathological studies might elucidate how the pathway from overexpression of DYRK1A to phosphorylation of tau is related to the severity of Alzheimer pathology.
Our study provides evidence that the DYRK1A gene is a genetic factor for AD, whose expression is increased by Ab loading in neuroblastoma cells and transgenic mice, resulting in hyperphosphorylation of tau at Thr 212 under overexpression of tau. The DYRK1A gene could be responsible for learning and memory deterioration in DS (24, 25) , and a DYRK1A inhibitor has been proposed as a novel drug to address learning and memory deficit in DS (49) . Our findings suggest that DYRK1A upregulation is a key phenomenon as a consequence of Ab loading in AD, connecting the condition to DS, and we propose a possible relation between the DYRK1A gene and memory impairment in AD.
MATERIALS AND METHODS
Sample-set characteristics
Patients with late-onset AD were diagnosed as having definite or probable AD according to the criteria of the National Institute of Neurological and Communicative Disorders and Stroke -Alzheimer's Disease and Related Disorders Association (50) . Non-demented control subjects, tested by a questionnaire including the date, orientation and past history, were obtained from population-based elderly subjects. Written informed consent to participate in this study was obtained, and then peripheral blood was drawn and subjected to DNA extraction. The number of patients for the scan was 374 (70.6% female), composed of 73 with definite and 301 with probable AD; mean + SD age at onset was 73.0 + 8.0, range 60 -94 years and age at blood drawing was 78.2 + 8.3, range 60 -98 years. Controls were composed of 375 individuals (54.7% female); age at assessment was 75.5 þ 4.85, range 66 -92 years. Brain hippocampal tissue was also obtained from the post-mortem brains of 22 patients with AD (age: 82.8 + 8.5 years, 63.6% female) and 12 pathological controls (age: 89.0 + 7.0 years, age at onset: 72.9 + 7.2 years and 58.0% female). DNA was extracted from peripheral blood nuclear cells by phenol -chloroform method or using a QIAamp DNA Blood Kit (Qiagen, Tokyo, Japan). The procedure to obtain the specimens was approved by the Genome Ethical Committee of Osaka University Graduate School of Medicine, Ehime University and the Ethical Committee of Fukushimura Hospital.
Genotyping and sequencing
An exploratory scan was performed in 188 patients (67.0% female) (age at onset: 75.0 + 7.2 and range 60-92 years) and 375 controls matched for age. A confirmatory scan was performed in 374 patients including 175 who underwent exploratory scan, and the data were compared with the genotype data of controls in the exploratory scan. The whole genomic DNA was amplified by degenerate oligonucleotide-primed-PCR and used in the confirmatory scan, because of the small amount of DNA (51) . The accuracy of genotyping in the confirmatory scan was monitored by comparison with data obtained in the exploratory scan. The selected markers were 417 SNPs distributed in chromosome 21, spanning a region of 33 Mb, which was sequenced and reported by the Chromosome 21 Mapping and Sequencing Consortium (18) . Mean interval of the markers in NCBI Build 35 was 78.1 kb, and their range was 7.7-240.0 kb, and 15 intervals were over 100 kb where no coding region was predicted on the basis of the SNP information in using SNPbrowser Software Version 3.5 on NCBI Build 35, available from http://www.appliedbiosystems.com/. Genotyping was performed by a quantitative genotyping method using the TaqMan SNP Genotyping System (Applied Biosystems, Foster City, CA, USA). DNA obtained from six patients and three controls homozygous for the risk genotype of the DYRK1A gene was subjected to direct sequencing of its exons, using the primers listed in Table 3 .
Quantitative real-time PCR
Total RNA was isolated from frozen brains using the acid guanidine -phenol -chloroform RNA extraction method provided as ISOGEN (Nippon Gene, Toyama, Japan), and purified using an RNAeasy Mini kit (Qiagen). RNA samples with an A 260 /A 280 absorption ratio over 1.9 were subjected to cDNA synthesis using a High-Capacity cDNA Archive Kit (Applied Biosystems). Quantitative real-time PCR was carried out in an ABI PRISM 7900HT (Applied Biosystems), and primers/probe sets for the DYRK1A and GAPDH genes of human and mouse were purchased from TaqMan Gene Expression Assay Products (Applied Biosystems). All quantitative PCR reactions were duplicated, and the ratio of the amount of DYRK1A cDNA to that of GAPDH internal control cDNA at a threshold in the mid-log phase of amplification was used to compare the amount of DYRK1A mRNA.
Transgenic mice
The PS1
I213T KI mouse, with a 'knocked-in' human PS1 I213T mutation in the mouse presenilin 1 gene (52, 53) , was bred with Tg2576 mice expressing the human APP gene harboring I213T KI mice were sacrificed at age 9 months under anesthesia, and their brains were dissected and stored at -808C until use. All animal procedures were reviewed by the Institutional Animal Care and Use Committee of Shionogi & Co., Ltd. Every effort was made to minimize the number of animals used and their suffering.
Cell culture
Human neuroblastoma (SH-SY5Y) cells were grown in F12 medium (Invitrogen, Carlsbad, CA, USA) with 10% fetal bovine serum (FBS) (JRH Bioscience, Lenexa, KS, USA), and human embryonic kidney (HEK293T) cells were grown in Dulbecco's modified Eagle's medium (Invitrogen) with 10% FBS. Amyloid peptides (Sigma-Aldrich, St Louis, MO, USA) were dissolved in phosphate-buffered saline, followed by incubation at 378C for 72 h. SH-SY5Y cells were incubated for 20 h with Ab at 0.5 mM for Ab1 -42 and at 25 mM for Ab25-35 and Ab35 -25. Total RNA was isolated from harvested cells using an RNAeasy Mini kit, and then synthesized cDNA was subjected to quantitative PCR. The human long isoform of MAPT cDNA, obtained from Dr Goedert (Medical Research Council Laboratory of Molecular Biology, Cambridge, UK), was cloned in pcDNA3.1 (Invitrogen), and the FLAG epitope-tagged DYRK1A expression vector was cloned in pEGFPC2 (55, 56) . These vectors were transfected into HEK293T cells using Lipofectamine 2000 (Invitrogen) in Opti-MEM (Invitrogen), followed by their expression for 24 h, and the cells were harvested and subjected to biochemical experiments.
Biochemical experiments
In transgenic mice, the hemisphere of each brain was homogenized in Tris-buffered saline (TBS) composed of 137 mM NaCl and 20 mM Tris, pH 7.6, containing 1% Triton X-100 with Complete TM protease inhibitor (Roche Diagnostics, Indianapolis, IN, USA), followed by ultracentrifugation, and the supernatant was subjected to measurement of Ab1-40 and Ab1-42 levels using a sandwich ELISA kit (Biosource International, Camarillo, CA, USA). In cell experiments, cells were lysed in lysis buffer composed of 150 mM NaCl, 50 mM Tris, pH 8.0, 1% NP-40, 0.1% sodium dodecyl sulfate (SDS), 0.5% sodium deoxycholate, protease inhibitor mixture (Sigma-Aldrich) and phosphatase inhibitor cocktail (Pierce, Rockford, IL, USA). After centrifugation at 10 000g for 15 min at 48C, protein extracts were obtained as the supernatant and quantified using BCA Protein Assay (Pierce). For immunoprecipitation, 300 mg of protein lysate was incubated with 20 ml anti-FLAG M2 agarose (Sigma-Aldrich) with gentle rotation at 48C overnight, and after centrifugation, the precipitate was dissolved in SDS sample buffer, electrophoresed in 8% SDS -PAGE and blotted onto nitrocellulose membranes (GE Healthcare Bio-Sciences, Piscataway, NJ, USA). After blocking with 5% milk in TBS buffer composed of 0.1% Tween-20, 140 mM NaCl and 10 mM Tris -HCl, pH 7.6, the membranes were incubated overnight at 48C with primary antibodies, such as polyclonal antibody to phosphotau (P-TauThr 212 ) (Biosource International) diluted to 1:500 or polyclonal antibodies to DYRK1A (Abcam, Cambridge, MA, USA) at 1:200 or to tau (Santa Cruz Biotechnology, Santa Cruz, CA, USA) at 1:500. The membranes were washed and then incubated with peroxidaseconjugated secondary antibodies against mouse, rabbit or sheep immunoglobulin (Promega, Madison, WI, USA), followed by washing and developing with an ECL Plus Western Blotting Detection System (GE Healthcare BioSciences). The immunoreactive bands on films were digitized with an HP 2355 and subjected to densitometric quantification using Image J version 1.36 (National Institute of Health).
Statistical analysis
To reduce type II errors, the exploratory and confirmatory scans were assessed for associations by one-sided chi-squared test for both allele and genotype frequencies in dominant and recessive models, where each a-level was 0.05. For markers showing significant associations in the confirmatory scan, the Hardy -Weinberg equilibrium was tested. The risk genotypes in the better fitting model were given a value of 1 and the other genotypes 0, and then logistic regression was performed along with age, sex and the APOE-14 dose under no interaction, using StatView software (SAS Institute, Cary, NC, USA). Linkage disequilibrium in the DYRK1A gene was also assessed by jD'j and r 2 values; those less than 0.9 and 0.5, respectively, were judged significant (57) . Case -control haplotype analysis was performed with the EM algorithm (58) and with the permutation test at 1000 iterations (59), using SNPAlyze software (DYNACOM, Japan). Normally distributed variables were compared by Student's t-test; otherwise non-parametric Mann -Whitney's U-test was applied. A P-value less than 0.05 was considered significant.
